Intravacc and EpiVax to develop Covid-19 vaccine candidate
Dutch research and development vaccine institute Intravacc has partnered with US-based biotechnology firm...
Focus:
-
![Regeneron; Intellia]()
Regeneron and Intellia to develop new haemophilia therapies
-
![Atea $215m Covid-19]()
Atea closes $215m Series D round to support Covid-19 trials
-
![Arcus Biosciences]()
Gilead and Arcus Biosciences partner to develop cancer drugs
-
![Praha Vaccines]()
Novavax buys Praha Vaccines for Covid-19 vaccine manufacturing
-
![AbCellera]()
AbCellera raises $105m for antibody drug discovery platform
-
![Merck covid-19 vaccines]()
Merck joins race to develop Covid-19 vaccines and drugs
Most Read
- Atea closes $215m Series D round to support Covid-19 trials
- PTC acquires Censa: diversifying into metabolic disease
- Rapid Micro Biosystems raises $120m: improving contamination testing in pharma
- Beyond M&As: will 2020 by the year of the spin-out?
- Vertex-Affinia partnership: expanding the gene therapy toolkit
Latest Content
Covid-19 pandemic: overcoming big pharma’s infectious disease market failure
Infectious diseases have been largely pushed to the wayside by big pharma because they are unable to bring the same profits as other conditions, such as cancer and chronic diseases. Octopus Ventures’ Uzma Choudry explains the reasons behind the failure and why she is hopeful the current Covid-19 pandemic will change attitudes towards the serious public health threats infectious diseases cause.
Intravacc and EpiVax to develop Covid-19 vaccine candidate
Dutch research and development vaccine institute Intravacc has partnered with US-based biotechnology firm EpiVax to advance a Covid-19 vaccine candidate.
AbbVie partners with Jacobio Pharmaceuticals for cancer drugs
AbbVie has collaborated with Jacobio Pharmaceuticals for the development and commercialisation of SHP2 inhibitors that act on an important node in cancer and immune cells.
Regeneron and Intellia to develop new haemophilia therapies
Regeneron Pharmaceuticals has expanded its ongoing partnership with Intellia Therapeutics for the development of therapies for haemophilia A and B.
Atea closes $215m Series D round to support Covid-19 trials
The Covid-19 pandemic has encouraged Atea to re-orient its work in the direct-acting antiviral space to treat the novel coronavirus. Its work to progress its lead candidate, AT-527, which has shown efficacy in other coronaviruses and hepatitis C, into a Phase II Covid-19 study will be supported by its $215m Series D funding round.
Novartis’ AveXis agrees to manufacture US researcher Covid-19 vaccine
Novartis unit AveXis has entered into a manufacturing agreement with researchers at Massachusetts Eye and Ear and Massachusetts General Hospital in the US to produce a genetic vaccine against Covid-19, named AAVCOVID.
Gilead and Arcus Biosciences partner to develop cancer drugs
Gilead Sciences has partnered with Arcus Biosciences to jointly develop and commercialise current and future cancer therapeutic candidates in the latter’s pipeline.
Novavax buys Praha Vaccines for Covid-19 vaccine manufacturing
Biotechnology firm Novavax has acquired Czech Republic-based Praha Vaccines for about $167m to support the manufacture of its Covid-19 vaccine candidate, NVX‑CoV2373.
AbCellera raises $105m for antibody drug discovery platform
Canadian biotech firm AbCellera Biologics has raised $105m in a Series B funding round to advance its artificial intelligence (AI)-powered antibody drug discovery platform.
Merck joins race to develop Covid-19 vaccines and drugs
Merck (MSD) has joined the race to develop vaccines and treatments against Covid-19 with three separate agreements with Themis, IAVI and Ridgeback Biotherapeutics.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top